Antibodies Against Citrullinated Peptides
A Role in the Diagnosis of Rheumatoid Arthritis
Development of Clinical Assays for Anti-Citrullinated Protein Antibodies
September 2008
As a result of the initial studies, development of clinical assays for anti-citrullinated protein antibodies focused on improving assay sensitivity while maintaining the high specificity. This was accomplished through optimization of protein or proteins used as a target antigen. During the course of this work, it was discovered that formation of a cyclic peptide improved the sensitivity of the assays.
To form these circularized structures, cystine residues were placed on either end of the peptide. When a disulfide bond was formed between the two cystine residues, a cyclic peptide resulted. This is where the term anticyclic citrullinated peptide antibody, or anti-CCP antibody, comes from. It is thought that the cyclic structure allows for maxim exposure of the citrullinated residue, thus improving analytic sensitivity.
Development of Clinical Assays |
Jump to section:
- Introduction
- Introduction to Connective Tissue Diseases
- Clinical Symptoms of Rheumatoid Arthritis
- Epidemiologic Features of Rheumatoid Arthritis
- Diagnostic Criteria for Rheumatoid Arthritis
- Utility of Rheumatoid Factor
- Discovery of Anti-Citrulline Antibodies
- Enzymatic Process of Citrullination
- Diagnostic Performance of Anti-Citrulline Antibodies
- Development of Clinical Assays for Anti-Citrullinated Protein Antibodies
- Development of Clinical Assays for Anti-Citrullinated Protein Antibodies
- Sensitivity and Specificity Comparison Anti-CCP and RF
- Diagnostic Algorithm for CTDs
- Summary
- Questions?
External
link
PDF
document
Excel
document
Word
document